All In Biotech

Drug Trial Radar · NCT00049998

Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

760

Actual

Start

Oct 2001

Primary completion

Apr 2004

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 20, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

  • topotecanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. One-year survival rate

Locations

114 sites in 31 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Adelaide, South Australia, Australia

  • GSK Investigational Site

    Bedford Park, South Australia, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Ringwood East, Victoria, Australia

  • GSK Investigational Site

    Innsbruck, Austria

  • GSK Investigational Site

    Sankt Pölten, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Braasschaat, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Sydney, Nova Scotia, Canada

  • GSK Investigational Site

    Oshawa, Ontario, Canada

  • GSK Investigational Site

    Thunder Bay, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Sainte-Foy, Quebec, Canada

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Tianjin, China

  • GSK Investigational Site

    Wangfujing, Beijing, China

  • GSK Investigational Site

    Xi'an, Shaanxi, China

  • GSK Investigational Site

    České Budějovice, Czechia

  • GSK Investigational Site

    Kladno, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Herlev, Denmark

  • GSK Investigational Site

    Odense C, Denmark

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Turku, Finland

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Dijon, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Toulon Naval, France

  • GSK Investigational Site

    Vesoul, France

  • GSK Investigational Site

    Gauting, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Regensburg, Bavaria, Germany

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.